Rimekor tab n / 20mg film about 30 pc


Rimekor tab n / 20mg film about 30 pc



Active substance:
Trimetazidine dihydrochloride 20 mg.
Ludipress, milk sugar (lactose), Aerosil (colloidal silicon dioxide), sodium croscarmellose, magnesium stearate.
Hydroxy-propilmetiltsellyuloza, titanium dioxide, talc, polyethylene glycol 4000, acid red.
Round biconvex tablets, film-coated, pink.
Product form:
Coated tablets 20 mg. 30 tablets in blisters. 1 contour cell package of 30 tablets together with instructions for use in a stack of cardboard.
Hypersensitivity to any component of the drug; severe renal impairment (creatinine clearance less than 15 mL / min); expressed human liver; pregnancy, lactation (breast-feeding); age 18 years (effectiveness and safety have been established); lactose intolerance, lactase deficiency or glucose-galactose malabsorption (formulation contains lactose).
20 mg
Ischemic heart disease: prevention of angina attacks (in the complex therapy);
Chorioretinal vascular disorders;
Vertigo of vascular origin;
Cochle-vestibular disorders ischemic nature (tinnitus, hearing impairment).
Interaction with other drugs
No information.
Data on cases of overdose is limited. In the case of an overdose should be symptomatic therapy.
pharmachologic effect
Pharmacological group:
Antihypoxanth means.
Trimetazidine has antianginal, antihypoxia action. Directly affecting the cardiomyocytes and neurons in the brain, it improves their metabolism and function. Cytoprotective effect is due to an increase in potential energy, the activation of the oxidative decarboxylation and the rationalization of oxygen consumption (increasing aerobic glycolysis and fatty acid oxidation blockade). Supports myocardial contractility, prevents a decrease in intracellular ATP and phosphocreatine. In acidosis conditions normalize the functioning of membrane ion channels and prevents the accumulation of calcium and sodium in cardiomyocytes normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content caused by myocardial ischemia and reperfusion. Prevents the damaging action of free radicals, preserves the integrity of cellular membranes, prevents activation of neutrophils in the ischemic area, increases the electric potential decreases the yield of creatine from the cells and the severity of ischemic myocardial injury.
When the frequency of attacks of angina reduces (decreases nitrate consumption) after 2 weeks of treatment increases exercise capacity, reduced blood pressure drops. Improved hearing and vestibular results of samples from patients, decreases dizziness and tinnitus.
When vascular eye disease restores the functional activity of the retina eyes.
After taking the drug inside Trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability – 90%. The time to reach maximum plasma concentration – 2 chasa (maximum concentration after a single dose of 20 mg of trimetazidine about 55 ng / ml). Easily penetrates the blood-tissue barriers. The half-life (T1 / 2) is 4.5-5 hours. Communication with plasma proteins – 16%. It is derived from the body by the kidneys (approximately 60% unchanged).
Conditions of supply of pharmacies
On prescription.
side effects
Distribution of the frequency of side effects produced according to the following gradation: very often – 1/10; often – more than 1/100 and less than 1.10; infrequently – more and less than 1/100 to 1/1000; rarely – more than 1/10000 and less than 1/1000; very rarely – less than 1/10000, including isolated reports.
From the digestive system: often – abdominal pain, diarrhea, dyspepsia, nausea, vomiting.
With the cardiovascular system: rarely – orthostatic hypotension, “tides” to the skin.
Central nervous system: often – dizziness, headache; very rarely – extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.
Skin and subcutaneous tissue: often – a rash, itching, hives.
Other: often – fatigue.
special instructions
The drug is not intended for the relief of angina attacks.
On the background of treatment in patients with coronary heart disease is a significant decrease in daily requirement of nitrates.
Use of the drug has no effect on the ability to control the car and the performance of work requiring a high rate of mental and physical reactions.
Storage conditions
In a dry place, protected from light, reach of children at a temperature not higher than 25 ° C.
Dosing and Administration
Inside, during a meal time.
The recommended dosing regime – 1 tablet (20 mg) 2-3 times a day (40-60 mg per day). The course of treatment recommended by the doctor.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review